Prosthetic Heart Valves

Prosthetic Heart Valves

Global Prosthetic Heart Valves Market to Reach US$12.3 Billion by 2030

The global market for Prosthetic Heart Valves estimated at US$7.4 Billion in the year 2023, is expected to reach US$12.3 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Transcatheter Heart Valves, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the Tissue Heart Valves segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 9.3% CAGR

The Prosthetic Heart Valves market in the U.S. is estimated at US$3.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 9.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Global Prosthetic Heart Valves Market - Key Trends & Drivers Summarized

Prosthetic heart valves are critical medical devices used to replace damaged or diseased heart valves, restoring normal blood flow and improving patient outcomes. These devices are typically categorized into two main types: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves, made from durable materials like titanium or carbon, are designed to last a lifetime but require patients to take anticoagulant medication indefinitely to prevent blood clots. Bioprosthetic valves, derived from animal tissues such as bovine or porcine heart valves, are less durable but do not usually necessitate long-term anticoagulation therapy. Both types of prosthetic heart valves are used to treat conditions such as aortic stenosis, mitral regurgitation, and other forms of valvular heart disease, which can severely impact cardiovascular function and overall health.

Technological advancements have significantly transformed the design and implantation procedures of prosthetic heart valves. Innovations such as transcatheter aortic valve replacement (TAVR) have revolutionized the field, providing a minimally invasive alternative to traditional open-heart surgery. TAVR allows for the implantation of a prosthetic valve via a catheter inserted through a small incision, typically in the femoral artery, reducing recovery times and complications, especially in high-risk patients. Additionally, improvements in imaging technologies, like 3D echocardiography and cardiac MRI, have enhanced preoperative planning and valve sizing, ensuring better fit and function. Advances in biomaterials have also contributed to the development of next-generation valves that mimic natural tissue properties more closely, offering improved durability and biocompatibility. Research is ongoing to develop valves that can grow and adapt with pediatric patients, addressing a critical need in congenital heart defect management.

The growth in the prosthetic heart valves market is driven by several factors, including the rising prevalence of valvular heart diseases, an aging population, and advancements in medical technology. The increasing incidence of heart valve disorders, often linked to age-related degeneration, rheumatic heart disease, and lifestyle factors such as hypertension and obesity, has led to greater demand for valve replacement procedures. The aging global population further exacerbates this demand, as older adults are more susceptible to heart valve conditions. Technological advancements, particularly in minimally invasive surgical techniques like TAVR, have expanded the candidate pool for valve replacement, including those previously deemed too high-risk for traditional surgery. Additionally, growing healthcare expenditure and improved access to medical services in developing regions are facilitating market expansion. The continuous development of more durable, biocompatible materials and the integration of advanced imaging and robotic technologies into surgical practice are also key drivers. These factors collectively highlight the dynamic growth and innovation within the prosthetic heart valves market, underscoring its critical role in enhancing cardiovascular health and patient quality of life.

Select Competitors (Total 28 Featured) -

• Abbott Laboratories, Inc.
• Boston Scientific Corporation
• Medtronic PLC
• St. Jude Medical, Inc.
• CryoLife, Inc.
• LivaNova PLC
• TTK Healthcare Ltd.
• Braile Biomedica
• Lepu Medical Technology (Beijing) Co., Ltd.
• Colibri Heart Valve LLC
• JenaValve Technology, Inc.
• Meril Life Sciences Pvt., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.